Nexalin Technology (NXL) Cash & Current Investments (2021 - 2026)
Nexalin Technology (NXL) posted quarterly Cash & Current Investments of $2.7 million for Q1 2026, up 32.05% year-over-year from $2.1 million in Q1 2025, and down 55.87% quarter-over-quarter from $6.1 million in Q4 2025.
Nexalin Technology (NXL) Cash & Current Investments (2021 - 2026) Analysis & Trends
Nexalin Technology's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 32.05% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (up 32.05% YoY), while the FY2025 annual figure was $6.1 million, up 76.35% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $2.7 million, down from $6.1 million in the prior quarter.
- The five-year high for Cash & Current Investments was $10.6 million in Q1 2023, with the low at $848796.0 in Q2 2024.
- The 5-year median for Cash & Current Investments is $5.8 million (2025), against an average of $5.5 million.
- The sharpest annual moves came in 2022 and 2024: Cash & Current Investments jumped 956.84% in 2022, then slumped 90.49% in 2024.
- Nexalin Technology's Cash & Current Investments stood at $7.0 million in 2022, then plunged by 57.84% to $2.9 million in 2023, then gained by 18.03% to $3.5 million in 2024, then surged by 76.35% to $6.1 million in 2025, then sank by 55.87% to $2.7 million in 2026.
- Business Quant data shows NXL's Cash & Current Investments at $2.7 million in Q1 2026, $6.1 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 5.60 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 3.48 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 9.22 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 539.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 4.25 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 1.95 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 2.11 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 3.32 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 482.30 Mn |
| 10 | Nexalin Technology | 7.04 Mn | 6.03 Mn | 8,897.00 | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 2.71 Mn |
| Dec 31, 2025 | 6.14 Mn |
| Sep 30, 2025 | 4.35 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | 9.02 Mn |
| Jun 30, 2024 | 848,796.00 |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 2.95 Mn |
| Sep 30, 2023 | 7.15 Mn |
| Jun 30, 2023 | 8.93 Mn |
| Mar 31, 2023 | 10.60 Mn |
| Dec 31, 2022 | 6.99 Mn |
| Sep 30, 2022 | 7.86 Mn |
| Dec 31, 2021 | 661,778.00 |